Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591289 | 1.00 | CA1 (0.36) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL1903347 | 0.97 | TSHR (0.33) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL1782970 | 0.92 | — | — | |
| Tert-Butyl Formate SCHEMBL27666929 | 0.81 | TDP1 (0.45) | — | |
| SCHEMBL1499965 | 0.79 | CA2 (0.36) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL7184574 | 0.78 | CA1 (0.39) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL27272 | 0.75 | KDM4E (0.37) | TSHRKMT2AALDH1A1KDM4E | |
| SCHEMBL4297335 | 0.75 | CA1 (0.33) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL9393882 | 0.75 | CA12 (0.42) | POLBTSHRKMT2AUSP2ALDH1A1 | |
| SCHEMBL7024974 | 0.74 | CA1 (0.48) | CA1CA2POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868031-B | Process for the preparation of N-alkoxycarbonylpiperidine derivatives and intermediates therefor | 有机合成药品工业株式会社 | 2023-10-03 | — | — | CN | claimed |
| EP-3741745-B1 | METHOD FOR PRODUCING N-ALKOXYCARBONYLPIPERIDINE DERIVATIVE, AND INTERMEDIATE THEREFOR | YUKI GOSEI YAKUHIN KOGYO KK (JP) | 2023-04-26 | — | — | EP | claimed |
| CN-111868031-A | Process for producing N-alkoxycarbonylpiperidine derivative and intermediate therefor | 有机合成药品工业株式会社 | 2020-10-30 | — | — | CN | claimed |
| CN-101735198-A | Novel method for preparing c-Met inhibitor PF22341066 | WUXI HOWFOND BIOPHARMA CO LTD | 2010-06-16 | — | — | CN | claimed |
| EP-1389188-B1 | METHOD FOR THE PRODUCTION OF BIPERIDEN II | FARMACEUTICO S I T SPECIALITA (IT) | 2006-06-28 | — | — | EP | claimed |
| US-6835839-B2 | Method for the production of biperiden II | ABBOTT GMBH & CO. KG (DE) | 2004-12-28 | — | — | US | claimed |
| US-20040152899-A1 | Method for the production of biperiden II | ABBOTT GMBH & CO. KG (DE) | 2004-08-05 | — | — | US | claimed |
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NEUROPN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | ASTRIZI BIO, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-12121515-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NeuroPn Therapeutics, Inc. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240294516-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | NeuroPn Therapeutics, Inc. (US) | 2024-09-05 | — | — | US | disclosed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2003082260-A2 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | SANDOZ AG (CH) | 2003-10-09 | — | — | WO | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| CN-1362954-A | Sulfamidohydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2002-08-07 | — | — | CN | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
| US-6066651-A | ANTITHROMBOTIC AGENTS BY VIRTUE OF THEIR ABILITY TO PREVENT PLATELET AGGREGATION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | CHEK1, CHEK2, BUB3 | CA1 4383/4885CA2 2731/4885POLB 640/4885 |
| US-20040152899-A1 | Method for the production of biperiden II | PDXK, PPIP5K2, EXOC1 | CA1 2927/4885CA2 907/4885POLB 1484/4885 |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | GLP1R, GIPR, GPR119 | CA1 4709/4885CA2 3252/4885POLB 3081/4885 |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PARK7, FAAH | CA1 4079/4885CA2 4249/4885POLB 1301/4885 |
| US-12121515-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | CA1 4358/4885CA2 4675/4885POLB 1586/4885 |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | CA1 4358/4885CA2 4675/4885POLB 1586/4885 |
| US-20240294516-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, HPGDS | CA1 4358/4885CA2 4675/4885POLB 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.